AMGN · Nasdaq · CIK 0000318154
AMGEN INC
AMGEN INC’s most recent SEC filing in our snapshot is a Form 3 filed on Oct 27, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $36.8B and net income of $7.7B, according to its XBRL data on EDGAR. Its EDGAR record lists 86 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- AMGEN INC
- Ticker
- AMGN
- SEC Central Index Key (CIK)
- 0000318154
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (code 2836)
- Business address
- THOUSAND OAKS, CA
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- SEC filer category
- Large accelerated filer
- Position in SEC ticker list
- #55 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from AMGEN INC’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |
| Net income | $5.9B | $6.6B | $6.7B | $4.1B | $7.7B |
| Diluted EPS | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 |
| Total assets | $61.2B | $65.1B | $97.2B | $91.8B | $90.6B |
| Cash and equivalents | $8.0B | $7.6B | $10.9B | $12.0B | $9.1B |
XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Feb 13, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 5, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Oct 27, 2026 | 8-K | Director or officer change· period Oct 26, 2026 | Document · Index |
| Apr 7, 2026 | DEF 14A | Definitive proxy statement· period May 19, 2026 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about AMGEN INC, by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Oct 27, 2026 | 3 | Initial statement of beneficial ownership· period Oct 26, 2026 | Document · Index |
| Oct 27, 2026 | 8-K | Director or officer change· period Oct 26, 2026 | Document · Index |
| Sep 4, 2026 | 3 | Initial statement of beneficial ownership· period Sep 1, 2026 | Document · Index |
| Aug 13, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 13, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 11, 2026 | Document · Index |
| Aug 12, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026 | Document · Index |
| Aug 11, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 10, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026 | Document · Index |
| Aug 10, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026 | Document · Index |
| Aug 10, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 7, 2026 | Document · Index |
| Aug 7, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 6, 2026 | Document · Index |
| Aug 7, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 6, 2026 | Document · Index |
| Aug 6, 2026 | 144/A | 144/A | Document · Index |
| Aug 6, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 6, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 5, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 4, 2026 | 8-K | Results of operations· period Aug 4, 2026 | Document · Index |
| Jul 31, 2026 | 8-K | Cybersecurity incident· period Jul 29, 2026 | Document · Index |
| Jun 11, 2026 | 11-K | Annual report of employee stock plans· period Dec 31, 2025 | Document · Index |
| Jun 11, 2026 | 11-K | Annual report of employee stock plans· period Dec 31, 2025 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 21, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 19, 2026 | Document · Index |
| May 20, 2026 | 8-K | Shareholder vote results· period May 19, 2026 | Document · Index |
| May 19, 2026 | 8-K | Director or officer change· period May 19, 2026 | Document · Index |
| May 14, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
Insider filing activity
86 Form 4 filings appear in AMGEN INC’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Biological Products, (No Diagnostic Substances)
- GILD GILEAD SCIENCES, INC.
- MRNA Moderna, Inc.
- ARGX ARGENX SE
- RVMD Revolution Medicines, Inc.
- BIIB BIOGEN INC.
- BNTX BioNTech SE
- EXEL EXELIXIS, INC.
- NBIX NEUROCRINE BIOSCIENCES INC
All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in California
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000318154 and XBRL company facts. AMGEN INC on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement